Renalytix reports positive study on clinical value of KidneyIntelX

Biotechnology company Renalytix announced the publication of new case studies in the Diabetic Nephropathy journal on Wednesday, highlighting the clinical value of ‘KidneyIntelX’ in risk stratification for the management of type-2 diabetes and chronic kidney disease (CKD).

The AIM-traded firm said the study emphasised the importance of early risk assessment to reduce the likelihood of progression to kidney failure and dialysis.

It said the case studies were carried out by a multidisciplinary clinical advisory panel that examined four different physicians' management of four patient cases using KidneyIntelX.

The study identified the lack of CKD education and patient awareness as barriers to care management in primary care settings.

It also emphasised the need for type-2 diabetic patients to learn about CKD management to improve health behaviour and medication compliance.

The study also noted that the lack of risk assessment tools in primary care often prevented the identification of high-risk patients in the early stages of CKD.

It described KidneyIntelX as a “bioprognostic tool” incorporating well-validated prognostic protein biomarkers, which could help to predict rapid kidney function decline in early-stage CKD patients.

The board said the proactive approach would help clinicians to optimise care and change the trajectory of chronic kidney disease before the onset of severe or irreversible kidney damage.

“This independent review reinforces the importance of KidneyIntelX early prognosis in patients with kidney disease and type-2 diabetes,” said the company’s chief medical officer Michael Donovan.

“These utility results were well represented in 'real-time' with the reported case studies and the introduction of the KidneyIntelX bioprognosis supporting clinical decision making and care optimisation across a spectrum of kidney event risk.”

At 1238 BST, shares in Renalytix were flat at 93p.

Reporting by Josh White for Sharecast.com.